好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Honing Discovery of Plasma Protein Biomarkers for Profiling Early Parkinson’s Disease Progression
Movement Disorders
S43 - Movement Disorders: Biomarkers, Mechanisms, and Pathophysiology (2:00 PM-2:12 PM)
006
To identify plasma biomarkers associated with early Parkinson’s disease (PD) progression
Biofluid biomarkers are desirable for assessing progression of and risk for PD when motor impairment is within range of neurologically healthy controls (HCs). Here, we developed protein quantitation standardization for sensitive detection of biomarkers, before motor deficits can be accurately scored.
We harnessed Olink Explore 1536 data from the Parkinson’s Progression Markers Initiative (PPMI) cohort (http://www.ppmi-info.org/) to discover biomarkers linked to PD pathophysiology. We stratified plasma protein markers with k-means clustering and used cluster content, age, sex, and plate ID among HCs to standardize protein quantitations for all markers in healthy controls, prodromal cases, and sporadic PD cases under 2 years of disease duration. The average standardized quantitation per subject of prodromal and PD cases were separately tested against those of HCs. Candidate prodromal markers were queried against UK Biobank (UKB) early PD data.
7 plasma proteins passed multiple-test correction for prodromal cases versus HCs. The 6 markers also measured in UKB-PPP shared the same direction of effect (one-sided Binomial test p = 0.02). 4 of the 7 were nominally significant in all three comparisons, and one protein, ITGAV, exhibited Bonferroni significant depletion in all comparisons. Standardizing quantitations enhanced discrimination of prodromals from HCs (AUC for ITGAV increased from 0.719 to 0.754, paired t test p = 0.01 for AUCs of 7 significant markers).

Adjusting for age, sex, and total protein levels during standardization of log-scale protein quantitations using trends from HCs is a straightforward approach to improve biomarker association and account for demographic factors correlated with disease status when evaluating marker performance. Accurate discrimination of HCs from early PD cases and monitoring molecular disease pathways is attainable with 5-10 plasma proteins.
Authors/Disclosures
David Brazel, PhD
PRESENTER 		Dr. Brazel has received personal compensation for serving as an employee of Octave Bio. Dr. Brazel has or had stock in Octave Bio. The institution of Dr. Brazel has received research support from MJFF. The institution of an immediate family member of Dr. Brazel has received research support from DOE/NASA/DOD.
Ludmila Voloboueva, PhD Dr. Voloboueva has received personal compensation for serving as an employee of Octave Bioscience.
Matthew Burrill, MS Mr. Burrill has received personal compensation for serving as an employee of Octave Bioscience. Mr. Burrill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Bioscience.
Katrina Paumier, PhD (Mitsubishi Tanabe Pharma America (MTPA)) Dr. Paumier has nothing to disclose.
Ferhan Qureshi (Octave Bioscience) Mr. Qureshi has received personal compensation for serving as an employee of Octave Bioscience.
Evan A. Boyle, PhD Mr. Boyle has received personal compensation for serving as an employee of Octave Bioscience. Mr. Boyle has received personal compensation for serving as an employee of Exai Bio. The institution of Mr. Boyle has received research support from Michael J Fox Foundation.